Caribou Biosciences Inc (NASDAQ: CRBU) kicked off on Tuesday, up 6.82% from the previous trading day, before settling in for the closing price of $1.32. Over the past 52 weeks, CRBU has traded in a range of $0.66-$3.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -33.41% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 4.47%. With a float of $80.97 million, this company’s outstanding shares have now reached $93.00 million.
In an organization with 147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 73.03%, operating margin of -2161.63%, and the pretax margin is -1954.67%.
Caribou Biosciences Inc (CRBU) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Caribou Biosciences Inc is 12.94%, while institutional ownership is 50.40%. The most recent insider transaction that took place on Mar 14 ’25, was worth 20,400. In this transaction President and CEO of this company bought 20,000 shares at a rate of $1.02, taking the stock ownership to the 3,369,395 shares. Before that another transaction happened on Feb 21 ’25, when Company’s Chief Legal Officer sold 3,564 for $1.35, making the entire transaction worth $4,811. This insider now owns 443,502 shares in total.
Caribou Biosciences Inc (CRBU) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 4.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.15% during the next five years compared to -33.41% drop over the previous five years of trading.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Take a look at Caribou Biosciences Inc’s (CRBU) current performance indicators. Last quarter, stock had a quick ratio of 7.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.40 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Caribou Biosciences Inc (CRBU)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was better than the volume of 1.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 90.32%.
During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 82.42%, which indicates a significant decrease from 92.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.18% in the past 14 days, which was lower than the 91.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9823, while its 200-day Moving Average is $1.4887. However, in the short run, Caribou Biosciences Inc’s stock first resistance to watch stands at $1.4583. Second resistance stands at $1.5067. The third major resistance level sits at $1.5733. If the price goes on to break the first support level at $1.3433, it is likely to go to the next support level at $1.2767. Assuming the price breaks the second support level, the third support level stands at $1.2283.
Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats
The company with the Market Capitalisation of 131.14 million has total of 93,005K Shares Outstanding. Its annual sales at the moment are 9,990 K in contrast with the sum of -149,110 K annual income. Company’s last quarter sales were recorded 2,350 K and last quarter income was -39,990 K.
